2011 Fiscal Year Final Research Report
A new strategy for the treatment of diabetic nephropathy : regulation of AMPK/ACC pathway in podocyte.
| Project/Area Number |
21591130
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Metabolomics
|
|---|
| Research Institution | Shiga University of Medical Science |
|---|
Principal Investigator |
ISSHIKI Keiji 滋賀医科大学, 医学部, 助教 (60378487)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MAEDA Shiro 独立行政法人理化学研究所, 内分泌代謝疾患研究チーム, チームリーダー (50314159)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Keywords | Acetyl-CoA carboxylase beta(ACCβ) / 5' AMP-activated protein kinase(AMPK) / 糸球体上皮細胞 / 糖尿病性腎症 / 腎内脂肪毒性 |
|---|
| Research Abstract |
Podocyte-specific overexpression of ACCbeta, a lipogenic enzyme, causes apoptosis, inflammation and reduction of slit-diaphragm proteins in podocytes. These structural and functional abnormalities in podocytes are related to the increase of albuminuria. The activation of AMPK, which suppresses the activity of ACCbeta, may be a new therapeutic target of podocyte injury in diabetic nephropathy by inhibiting the activity of ACCbeta in podocytes
|
